

## Left Ventricular Assist Devices and the Kidney

Daniel W. Ross,<sup>1</sup> Gerin R. Stevens,<sup>2</sup> Rimda Wanchoo,<sup>1</sup> David T. Majure,<sup>2</sup> Sandeep Jauhar,<sup>2</sup> Harold A. Fernandez,<sup>3</sup> Massini Merzkani,<sup>1</sup> and Kenar D. Jhaveri<sup>1</sup>

### Abstract

Left ventricular assist devices (LVADs) are common and implantation carries risk of AKI. LVADs are used as a bridge to heart transplantation or as destination therapy. Patients with refractory heart failure that develop chronic cardiorenal syndrome and CKD often improve after LVAD placement. Nevertheless, reversibility of CKD is hard to predict. After LVAD placement, significant GFR increases may be followed by a late return to near baseline GFR levels, and in some patients, a decline in GFR. In this review, we discuss changes in GFR after LVAD placement, the incidence of AKI and associated mortality after LVAD placement, the management of AKI requiring RRT, and lastly, we review salient features about cardiorenal syndrome learned from the LVAD experience. In light of the growing number of patients using LVADs as a destination therapy, it is important to understand the effect of these devices on the kidney. Additional research and long-term data are required to better understand the relationship between the LVAD and the kidney.

*Clin J Am Soc Nephrol* 13: 348–355, 2018. doi: <https://doi.org/10.2215/CJN.04670417>

### Introduction

Five and a half million Americans suffer from congestive heart failure (CHF) (1) and many have CKD. The pathogenesis of CKD in patients with CHF is multifactorial (2). In patients with advanced CHF refractory to medical therapy, implantable left ventricular assist devices (LVADs) improve survival and quality of life (3). LVADs are used as a bridge to transplantation or as destination therapy in patients ineligible for heart transplant. Kidney function often improves after LVAD, but hemodynamic instability and right ventricular failure postoperatively may cause AKI. Early postimplant gains in GFR may be followed by a gradual decline in GFR with long-term LVAD support (4). It is paramount for nephrologists to become familiar with managing these patients. Here, we will review (1) early and long-term changes in GFR after LVAD implantation, (2) the incidence and outcomes of AKI immediately after LVAD implantation, (3) the lessons learned about cardiorenal syndrome from the LVAD experience, and (4) the management of AKI requiring RRT.

### The Basics of LVADs

The typical configuration of all LVADs includes the implantable pump, an externalized power cord (*i.e.*, driveline), and a power source (*i.e.*, batteries), as shown in Figure 1. Although the first-generation LVADs (HeartMate XVE) improved 1-year survival compared with medical therapy alone (52% versus 25%;  $P < 0.05$ ) in patients who are ineligible for heart transplant, they suffered from mechanical and infectious complications (3). LVADs in current use include the HeartMate II left ventricular assist system (Abbott, Inc., Pleasanton, CA), an axial flow pump, and the HeartWare HVAD (Medtronic, Inc., Framingham,

MA), a magnetically levitated, centrifugal flow pump, both of which are continuous flow, or “nonpulsatile” by design. Patients are treated with antiplatelet and anticoagulant medications, typically a combination of aspirin and warfarin, to reduce the risk of clot formation within the device and of embolic events through the device, such as stroke (1,2,5–7). LVADs drain blood from the left ventricular apex through an inflow cannula, passing through the pump machinery, and returning to the arterial system *via* a graft to the ascending aorta (Figure 1). It is powered by a driveline that exits along the lateral abdominal wall and is connected to a battery-driven controller. The mechanical shear stress on red blood cells as they move through the pump causes continuous low-level hemolysis, which is monitored by following serum lactate dehydrogenase levels. In addition, there is a well documented breakdown of the large vWf multimer leading to acquired von Willebrand disease, which has been associated with arteriovenous malformations in mucous membranes that can lead to severe epistaxis and gastrointestinal bleeding (7).

The HeartMate 3 is under clinical investigation and is also a magnetically levitated, centrifugal flow pump, but engineered to create “pulsatility” by programmed speed changes (6). Initial analysis at 6 months postimplant revealed no episodes of pump thrombosis in the HeartMate 3 group (centrifugal flow) compared with 10.1% in the HeartMate II (axial flow) group, but with no difference in mortality or disabling stroke (6).

### AKI and Patient Outcomes in the Postoperative Period

Although kidney function improves after LVAD implantation, the incidence of early AKI ranges from 15% to 45% (Table 1). Incidence of AKI does not differ


<sup>1</sup>Division of Kidney Diseases and Hypertension, Department of Medicine,

<sup>2</sup>Department of Cardiology, and

<sup>3</sup>Department of Cardiothoracic Surgery, Hofstra Northwell School of Medicine, Northwell Health, North Shore University Hospital, Manhasset, New York

### Correspondence:

Dr. Kenar D. Jhaveri, Division of Kidney Diseases and Hypertension, Department of Medicine, Hofstra Northwell School of Medicine, 100 Community Drive, Great Neck, NY 11021. Email: [kjhaveri@northwell.edu](mailto:kjhaveri@northwell.edu)



**Figure 1. | Components of the HeartMate II.** (A) HeartMate II LVAD. The device has four components: implantable pump, driveline, external power source (e.g., batteries), and a system controller. Blood travels from the apex of the left ventricle through the inflow cannula, into the pump, and out *via* a graft that is attached to the ascending aorta and to the systemic circulation effectively bypassing the aortic valve. The system controller has a display screen that shows key device parameters. Power must always be supplied by two sources, either both batteries or *via* the power module, which is used in the home during sleeping hours. (B) A closeup of the HeartMate II system controller. Patients or caregivers can scroll through the different parameters (speed, flow, power, and pulsatility index) by pushing a button on the controller. One can also determine the amount of charge left in the batteries to avoid running too low. Images provided courtesy of St. Jude Medical, Inc. LVAD, left ventricular assist device.

between patients implanted with pulsatile or continuous flow pumps (8). Table 1 shows that the reported incidence of AKI has not changed over the years. AKI is associated with high mortality, and the need for RRT ranges from 6% to 32% and is also associated with increased mortality.

Early AKI may result from hemodynamic instability. Table 2 highlights predictors of AKI. Topkara *et al.* (9) showed that patients with postoperative kidney failure requiring dialysis were older (mean age of 53 years), had a higher incidence of intra-aortic balloon pump (IABP) use (47% versus 26%), a higher preoperative mean LVAD score, and lower mean total protein (5.8 g/dl versus 6.4 g/dl) and albumin levels (1.2 g/dl versus 3.3 g/dl). This particular LVAD score includes (1) postimplantation shock, (2) ventilatory status, (3) central venous pressure >16 mm Hg, and (4) prothrombin time >16 seconds (9).

Right ventricular failure plays a large role in postoperative AKI. Right ventricular failure contributes to decreased renal arterial blood flow, urine volume, and deterioration in GFR (10). Pre- and postimplantation prevention of AKI is synonymous with prevention and/or management of right ventricular failure, if LVAD parameters and BP have been optimized. Strategies include maintaining coronary perfusion pressure (e.g., relatively high mean arterial pressure (MAP) and relatively low central venous pressure), reducing wall tension with IABP, diuresis, and maintaining right ventricular cardiac output *via* inotropes. A MAP target of 70–80 mm Hg and central venous pressures of 8–12 mm Hg are recommended. Diuresis or ultrafiltration may be necessary to achieve these goals. In cases of severe right ventricular failure, placement of a temporary right ventricular assist device may improve kidney function. By decreasing right-sided filling pressure and increasing cardiac output, adding a right ventricular assist device can provide a more favorable arteriovenous pressure gradient across the kidney. However, outcomes of patients who require biventricular devices are poor (11). There are no approved permanent right ventricular assist devices in the United States. Few centers have experience in bilateral device placements, but it is not common practice in the United States and outside the scope of this review.

Patients who develop AKI after LVAD have a survival disadvantage, particularly if RRT is required (12). Patients who require dialysis are less likely to go on to transplantation compared with those without AKI (52% versus 84%) (9). Genovese *et al.* (13) found that AKI was the only early major adverse event associated with 1-year mortality post-implantation. Postoperative AKI is associated with a higher incidence of postoperative right ventricular failure, ventricular arrhythmias (9), infections, and liver injury (14). Brisco *et al.* (14) observed that large early gains in GFR are associated with subsequent declines to near baseline levels. It is possible that patients with extreme cardiomyopathy see the greatest benefit to change in kidney perfusion with improved cardiac output. These patients have an improvement in their GFR but have a high overall mortality associated with the severity of their underlying disease (13).

### Early and Late Changes in Kidney Function with LVAD Implantation

Changes in kidney function after LVAD implantation have been explored in multiple studies with conflicting results (15,16). For most patients, LVAD support optimizes circulation and improves kidney function (17). Recovery of kidney function after LVAD implantation has been investigated in different cohorts (15–17), including in patients

Table 1. AKI incidence and mortality after left ventricular assist device implantation

Reference	Device	Flow Type	LVAD, n	AKI Criterion	AKI Incidence, % (N)	AKI Dialysis, % (N)	Mortality in AKI versus No AKI
Topkara <i>et al.</i> (9)	Heartmate	C and P	201	Requirement for CRRT	N/A	32 (65)	57% versus 28% at 1 yr
McCarthy <i>et al.</i> (13)	Heartmate	P	100	AKI = requirement for CRRT	N/A	N/A	63% versus 14% in the immediate postoperative period
Frazier <i>et al.</i> (47)	Heartmate	P	280	AKI = Cr >2.2 mg/dl or BUN >50 mg/dl	56 (156)	N/A	N/A
Haddad <i>et al.</i> (48)	Heartmate	P	54	AKI = need for RRT	7 (4)	N/A	N/A
Alba <i>et al.</i> (10)	Abiomed BV5000, Toratec, Novacor, VE Heartmate, Heartmate II	C and P	53	RIFLE	45 (24)	28 (15)	55% versus 7% ( $P<0.01$ ) at 30 d
Kaltenmaier <i>et al.</i> (12)	Novacor, Heartmate 2000, Berlin Heart System	C	227	Requirement for RRT	N/A	24 (55)	62% versus 39% ( $P<0.01$ ) at 30 d
Deng <i>et al.</i> (49)	Multiple	C and P	412	AKI not defined	21 (85)	N/A	N/A
Feller <i>et al.</i> (50)	Heartmate Novacor	C and P	27	AKI = need for RRT	22 (6)	N/A	N/A
Miller <i>et al.</i> (38)	Heartmate II	C	133	AKI not defined	14 (18)	N/A	N/A
John <i>et al.</i> (51)	Heartmate II	C	1496	RRT or Cr increase $\geq 3$ times baseline or Cr >5.0 for 48 h	9 (129)	N/A	N/A
Aaronson <i>et al.</i> (7)	HeartWare	C	140	RRT or Cr increase $\geq 3$ times baseline or Cr >5.0 for 48 h	5.7 (8)	N/A	N/A
Hasin <i>et al.</i> (4)	Heartmate II	C	83	N/A	N/A	9.6 (8)	N/A
Borgi <i>et al.</i> (52)	Heartmate II or HeartWare	C	100	RIFLE	28 (28)	9 (9)	0% versus 18% ( $P<0.01$ ) at 30 d
Slaughter <i>et al.</i> (5)	HeartWare	C	332	RRT or Cr increase $\geq 3$ times baseline or Cr >5.0 for 48 h	5.1 (17)	N/A	N/A
Brisco <i>et al.</i> (14)	Multiple	C	2476	eGFR decrease >25%	7.4 (183)	N/A	10% mortality in those with AKI
Sandner <i>et al.</i> (16)	HeartWare Novacor	C and P	69	AKI = RRT	47 (33)	N/A	78% for pulsatile and 62% for continuous flow at 6 mo
Sandner <i>et al.</i> (53)	DuraHeart DeBakley DeBakley HeartWare	C	86	AKI = RRT	35 (30)	N/A	71% with AKI versus 22% with no AKI
Demirozu <i>et al.</i> (36)	DuraHeart Heartmate II	C	107	AKI = RRT	N/A	14 (15)	N/A
Genovese <i>et al.</i> (13)	Novacor Heartmate II	C and P	163	AKI was not defined	13 (22)	N/A	68% with AKI versus 35% no AKI (1 yr)
Starling <i>et al.</i> (54)	Multiple	C	169	AKI was not defined	10 (17)	N/A	N/A
Park <i>et al.</i> (55)	Heartmate II	C	414	AKI was not defined	51 (12)	N/A	N/A
Naik <i>et al.</i> (56)	N/A	C	157	RIFLE	28 (44)	5.7 (9)	26% versus 8% ( $P<0.01$ )

LVAD, left ventricular assist device; C, continuous flow LVAD; P, pulsatile flow LVAD; CRRT, continuous RRT; N/A, not available; RIFLE, Risk Injury Failure Loss and ESRD; Cr, creatinine.

Preoperative	Intraoperative	Postoperative
Serum creatinine >1.5 mg/dl Worse right ventricular function Older age Higher LVAD score <sup>a</sup> Malnourishment (low albumin, total protein) Kidney size <10 cm Renin-angiotensin system inhibitors use immediately before surgery	Longer cardiopulmonary bypass time Bleeding (>1 L) Number of transfusions	Intra-aortic balloon pump Reoperation Liver dysfunction Sepsis High central venous pressure

LVAD, left ventricular assist device.  
<sup>a</sup>LVAD score is a measurement of illness severity derived from the following factors in HeartMate II: (1) postimplantation shock, (2) ventilatory status, (3) central venous pressure >16 mm Hg, and (4) prothrombin time >16 s.

with CKD (16). For most patients with end-stage CHF being considered for LVAD implantation, kidney injury was reversible and likely related to poor kidney perfusion. Hasin *et al.* (4), with preimplant eGFR <60 cc/min, showed an improvement to >60 cc/min after the first month. Brisco *et al.* (14) reported a median improvement in GFR of around 50% by 1 month, and eGFR doubled in 17% of patients. In some studies, no improvement in kidney function was observed after 1 month (14,16). This may be due to the patient’s underlying intrinsic kidney disease, diabetes, hypertension, renovascular disease, or ongoing volume overload or low output due to CHF despite LVAD implantation.


Hasin *et al.* (4) showed that younger age, GFR improvement with optimal medical therapy, IABP use, kidney size >10 cm, no treatment with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, higher bilirubin, higher Lietz–Miller score (a risk score in HeartMate XVE patients ineligible for heart transplant and not validated in current LVADs), and atrial fibrillation were univariate preimplant predictors for improvement in kidney function at 1 month. Multivariate analysis showed improved GFR with optimal medical therapy and IABP as independent predictors of postoperative improvement in kidney function. In our opinion, patients with cardiorenal syndrome type 2 are more likely to have improved GFR than patients with underlying primary kidney disease.

Even when kidney function improves at 30 days, there can be a subsequent decline. In approximately 3000 patients, Brisco *et al.* (14) showed that median preimplant GFR was 61 ml/min per 1.73 m<sup>2</sup>, and improved to 80 ml/min per 1.73 m<sup>2</sup> at 1 month. At 1-year postimplantation, the median improvement in GFR was 2.6 ml/min per 1.73 m<sup>2</sup> over the preimplant level. This pattern of improvement and then decline was consistent, regardless of device strategy or severity of illness (14).

Three likely mechanisms for late kidney impairment are postulated: (1) chronic hemolysis, (2) diminished pulsatility resulting from continuous flow, and (3) progressive right ventricular failure (Figure 2). Hemolysis is seen with continuous flow LVADs and is thought to result from shear stress as blood travels through the pump (3). This leads to red blood cell breakdown and release of free hemoglobin. In the presence of pump thrombosis, laminar

flow is disrupted, platelet aggregation and deposition occur, and shear forces increase. Pigment nephropathy from hemolysis is documented (18), and patients present with hemoglobinuria and AKI. In one case report, a kidney biopsy of a patient post-LVAD implantation demonstrated subclinical iron/hemosiderin deposition in tubular cells (18).

Right ventricular failure can develop at any time during LVAD support and has several etiologies. The Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) defines right-sided heart failure as an elevated central venous pressure and findings of one of the following: peripheral edema, ascites, hepatomegaly, worsening hepatic function (total bilirubin >2.0), or renal dysfunction (serum creatinine >2.0) (19). A measured central venous pressure >16 mm Hg, findings of a dilated inferior vena cava with absence of inspiratory variation by echocardiography, or clinical findings of jugular venous distention at least halfway up the neck in an upright patient suggest clinical signs of right-sided heart failure. Furthermore, the need for prolonged inotropes, inhaled vasodilators, or right ventricular assist device support post-LVAD implantation indicates the severity of right ventricular dysfunction.



**Figure 2. | Many factors contribute to early and late AKI after LVAD.** Postulated mechanisms of immediate AKI and late stage AKI. ATN, acute tubular necrosis; CHF, congestive heart failure.

Normalizing left ventricular cardiac output post-LVAD implantation leads to increased blood return to an impaired right ventricle, which can worsen right-sided heart failure and lead to AKI from renal venous hypertension (20–22). Alternatively, too little flow through the LVAD leads to high right ventricular afterload, which can also lead to right-sided heart failure. Recognizing the effect of right-sided heart function on the kidney is important, and efforts to maximize hemodynamics post-LVAD implantation can help prevent decline in kidney function. We recommend aggressive diuresis and ultrafiltration as needed when right ventricular failure is suspected in the setting of AKI.

Lack of pulsatile flow in the kidney is an active area of research. The nonpulsatile nature of continuous flow LVADs may contribute to kidney function decline. Animal models have shown that prolonged continuous flow causes changes in the aortic wall, including medial degeneration, smooth muscle cell depletion, and medial fibrosis (23,24). This leads to decreased peripheral vascular reactivity and stiff, poorly compliant vessels (25,26). Animal studies of continuous flow in the kidney found proliferation of smooth muscle cells in the afferent arterioles in the renal cortex and severe periarteritis (26). Periarteritis leads to upregulation of the local renin-angiotensin aldosterone system (RAAS) in the kidney (26). Although this mechanism has not been demonstrated in humans, this may partially explain the late decline in GFR in patients post-LVAD implantation. It will be interesting to review the HeartMate 3 experience, given the asynchronous pulsatile design achieved by programmed speed changes, and to assess its effect on kidney function. Interestingly, analysis of the INTERMACS data reveals that gradual late decline in GFR was observed with both continuous and pulsatile flow LVADs, hinting that pulsatility cannot be the sole mechanism of kidney injury (14). In summary, late decline in GFR is likely multifactorial and may be related to (1) hemolysis, (2) right ventricular failure, and/or (3) lack of pulsatile flow.

### Lessons Learned about the Cardiorenal Syndrome from the LVAD Experience

Cardiorenal syndrome is classified into five variants (27,28) (Table 3). Type 2 cardiorenal syndrome is of particular interest in patients with an LVAD. In these patients, high renal venous pressures and inflammation cause progression of CKD (27). CHF leads to increases in renal venous congestion and high intratubular pressure, which decreases filtration fraction and GFR (29,30). Other pathologic factors in type 2 cardiorenal syndrome include activation of systemic RAAS and sympathetic activation, leading to upregulation of the local kidney RAAS (31). LVAD implantation reverses some of these mechanisms. Most of the immediate kidney function improvement noted with implantation of LVADs is likely a result of decreased renal venous congestion (27). In addition, improvement in cardiac output and renal arterial blood flow often helps recovery of the AKI. But there is evidence that there is also a reduction of sympathetic tone and downregulation of RAAS after LVAD placement (32–34). James *et al.* (35) found that in patients being bridged to transplant, plasma

**Table 3. Definition and classification of cardiorenal syndromes (28)**

Cardiorenal syndromes general definition: Disorders of the heart and kidneys whereby acute or chronic dysfunction in one organ may induce acute or chronic dysfunction of the other.

Acute cardiorenal syndrome (type 1): Acute worsening of the cardiac function leading to renal dysfunction.

Chronic cardiorenal syndrome (type 2): Chronic abnormalities in cardiac function leading to renal dysfunction.

Acute renocardiac syndrome (type 3): Acute worsening of renal function causing cardiac dysfunction.

Chronic renocardiac syndrome (type 4): Chronic abnormalities in renal function leading to cardiac disease.

Secondary cardiorenal syndrome (type 5): Systemic conditions causing simultaneous dysfunction of the heart and the kidney.

renin activity and plasma aldosterone levels decreased significantly from baseline after implantation of LVAD. Post-transplantation, after more than 45 days on LVAD support, both plasma renin activity and angiotensin II levels decrease (34). This suggests that the RAAS activation in CHF is meaningfully reduced after LVAD implantation or heart transplantation, providing biochemical confirmation of the improvement in hemodynamic status (32). In summary, the LVAD experience has shed light on the cardiorenal syndrome and has underscored the importance of RAAS and renal venous hypertension.

### Dialysis in Patients with LVADs

A minority of patients with AKI after LVAD will require dialysis. The incidence of needing RRT ranges from 11% to 33% (36). In the initial phase of AKI, most patients are on continuous RRT. Some patients will stabilize and be transitioned to intermittent RRT. For nephrologists, there are three major questions that need to be answered.

#### First, Is Hemodialysis Safe in Patients with an LVAD?

Quader *et al.* (37) reviewed ten patients that required hemodialysis (HD) on LVAD support. A total of 281 HD sessions were administered for 1025 hours. Only 5.3% of sessions were interrupted, and only two of these were for low flow LVAD alarms. No serious adverse events were noted in these patients.

#### Second, Can Arteriovenous Fistulas Mature without Pulsatile Flow?

No trials have evaluated the patency of arteriovenous fistulas (AVFs) in patients with an LVAD. Prior recommendations from experts have advocated for arteriovenous grafts as the first option (38). However, new evidence suggests that successful HD *via* AVF is possible. Three publications described eight cases where AVF maturation proceeded normally. There were no hemodynamic or infectious complications reported (39–41). Two patients required secondary intervention, but eventually

the AVFs functioned well (41). In our opinion, AVFs can be used successfully in patients with continuous flow LVADs. AVF should be considered as the first choice, given the infection risk associated with arteriovenous grafts.

### Third, What Modality Is Preferred: HD or Peritoneal Dialysis?

HD is the default option, but peritoneal dialysis (PD) should be given strong consideration because of the slow continuous nature of ultrafiltration. PD is a viable option in the newer continuous flow LVADs as they are placed in the preperitoneal position (6). Before PD catheter insertion, it is important to evaluate the course of the driveline as it can sometimes pass through the peritoneum. A concern with patients with an LVAD is infection of the driveline exit site, so the PD catheter should be placed far away from this area. In addition, PD peritonitis is still less common compared with HD catheter-related infections leading to bacteremia. Overall, PD offers three benefits over HD: (1) continuous ultrafiltration, (2) low risk of systemic infection from bacteremia, and (3) ease of home modality. Results with PD in patients with an LVAD are encouraging (42,43), but because of lack of any randomized, controlled trials and comfort level of both cardiologist and nephrologists, the superiority of PD cannot be claimed.

### Troubleshooting in the Dialysis Unit

Educating dialysis nurses is paramount. Nurses must be capable of responding to LVAD alarms and communicating with the LVAD team. Three numbers are important to know: pump speed, pump flow rate, and the pulsatility index in HeartMate II (38,44). The pump speed is the rate of revolution of the rotor. Pump flow is derived from the pump speed and power, and is inversely related to the pressure differential across the pump. The pulsatility index is a dimensionless figure that is derived from the LVAD pump (45). Despite the presence of an LVAD, the native ventricle can have residual pulsatile activity that transiently increases flow within the LVAD resulting in a flow pulse. When the ventricle has native contractile function, then the resulting flow pulses will cause the pulsatility index to increase. When preload decreases, the contractility of the left ventricle and the pulsatility index decrease. A low pulsatility index alarm can indicate excessive ultrafiltration.

BP is challenging to monitor during dialysis in a patient with a continuous flow LVAD as many patients often have no pulse (46). Residual left ventricular function can yield some pulse pressure and a sphygmomanometer may be tried in these patients (53%) (46). Doppler audible ultrasound with calibrated BP measurement devices are used in most centers to get an MAP reading. MAP can be measured by placing the Doppler probe over the brachial artery and inflating the cuff using the nonaccess arm. Continuous flow LVAD devices are sensitive to elevated afterload. Increased afterload can reduce pump output and/or cause retrograde flow through the LVAD because of the absence of valves in the device. As a result, it is important to monitor for elevated BP and treat accordingly. The MAP that is optimal is between 70 and 80 mm Hg, and

**Table 4. Challenges faced by the nephrologist and dialysis nurses in the hemodialysis unit and with left ventricular assist devices**

#### Volume status

- Numbers 1–3 appear on the LVAD screen
- (1) Pump speed: rate of revolution of rotor  
*Higher speed leads to higher flow, usually 3–10 L/min*
  - (2) Pump flow rate: derived from pressure differential across pump
  - (3) Pulsatility index: related to native ventricular pulsatility  
*When preload decreases then pulsatility index decreases*  
*Low pulsatility index can indicate excessive ultrafiltration*

#### BP measurement

- Use a Doppler audible ultrasound with calibrated BP device
- Place Doppler probe over brachial artery and inflate cuff
- Listen for flow as cuff is deflated to get the mean arterial pressure
- Ideal mean arterial pressure is 70–80 mm Hg, and should not exceed 90 mm Hg

must not be allowed to exceed 90 mm Hg. When initiating antihypertensive therapy, negative inotropes should be used with caution and in collaboration with the LVAD treatment team. The antihypertensive agents of choice in this population are angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. In patients with AKI and CKD, hydralazine provides adequate control. Table 4 summarizes the challenges faced by the dialysis team with a patient with an LVAD.

### Conclusion

LVAD implantation improves hemodynamics *via* restoration of blood flow and decreases in ventricular filling pressures. The effect of LVAD support on kidney function is complex. As knowledge of LVADs and kidney disease grows, some of our opinion-based recommendations (Table 5) may change with time.

**Table 5. Expert opinion on kidney dysfunction and left ventricular assist devices (LVADs)**

#### Expert opinion review on renal disease with LVADs

- Identify and treat early right ventricular dysfunction with aggressive diuresis and ultrafiltration as needed
- Hemodialysis and peritoneal dialysis can be safely performed in patients with an LVAD in the outpatient setting
- Arteriovenous fistulas should be the first choice of chronic access for patients on hemodialysis
- Peritoneal dialysis should be considered in patients with an LVAD given slow continuous ultrafiltration
- Interdisciplinary teams including cardiologists, nephrologists, and nursing staff should be developed

Major impairment of kidney function preoperatively is a risk factor for AKI. Because AKI postimplantation confers a high mortality, preimplant kidney dysfunction should be strongly considered in discussions regarding candidacy. Known risk factors such as age, right ventricular dysfunction, malnutrition, and intraoperative blood loss importantly affect outcomes with this lifesaving device. Careful assessment of risk factors and early involvement of a nephrologist in the LVAD planning team may help improve outcomes. The advent of continuous flow LVADs has taught us the various factors involved in type 2 cardiorenal syndrome and can help further assist in management. LVAD patients on dialysis require expert communication between the LVAD and dialysis teams. Further studies are needed to aid in identifying patients with CKD who are most likely to benefit from LVADs.

#### Acknowledgments

We would like to thank our medical librarian, Ms. Janice Lester at Northwell Health, in the search strategy utilized in obtaining articles related to our review topic.

#### Disclosures

None.

#### References

- Roger VL, Weston SA, Redfield MM, Hellermann-Homan JP, Killian J, Yawn BP, Jacobsen SJ: Trends in heart failure incidence and survival in a community-based population. *JAMA* 292: 344–350, 2004
- Patel UD, Hernandez AF, Liang L, Peterson ED, LaBresh KA, Yancy CW, Albert NM, Ellrodt G, Fonarow GC: Quality of care and outcomes among patients with heart failure and chronic kidney disease: A get with the guidelines – heart failure program study. *Am Heart J* 156: 674–681, 2008
- Rose EA, Gelijs AC, Moskowitz AJ, Heitjan DF, Stevenson LW, Dembitsky W, Long JW, Ascheim DD, Tierney AR, Levitan RG, Watson JT, Meier P, Ronan NS, Shapiro PA, Lazar RM, Miller LW, Gupta L, Frazier OH, Desvigne-Nickens P, Oz MC, Poirier VL; Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) Study Group: Long-term use of a left ventricular assist device for end-stage heart failure. *N Engl J Med* 345: 1435–1443, 2001
- Hasin T, Topilsky Y, Schirger JA, Li Z, Zhao Y, Boilson BA, Clavell AL, Rodeheffer RJ, Frantz RP, Edwards BS, Pereira NL, Joyce L, Daly R, Park SJ, Kushwaha SS: Changes in renal function after implantation of continuous-flow left ventricular assist devices. *J Am Coll Cardiol* 59: 26–36, 2012
- Slaughter MS, Rogers JG, Milano CA, Russell SD, Conte JV, Feldman D, Sun B, Tatooles AJ, Delgado 3rd RM, Long JW, Wozniak TC, Ghumman W, Farrar DJ, Frazier OH; HeartMate II Investigators: Advanced heart failure treated with continuous-flow left ventricular assist device. *N Engl J Med* 361: 2241–2251, 2009
- Mehra MR, Naka Y, Uriel N, Goldstein DJ, Cleveland Jr. JC, Colombo PC, Walsh MN, Milano CA, Patel CB, Jorde UP, Pagani FD, Aaronson KD, Dean DA, McCants K, Itoh A, Ewald G, Horstmannshof D, Long JW, Salerno C; MOMENTUM 3 Investigators: A fully magnetically levitated circulatory pump for advanced heart failure. *N Engl J Med* 376: 440–450, 2017
- Aaronson KD, Slaughter MS, Miller LW, McGee EC, Cotts WG, Acker MA, Jessup ML, Gregoric ID, Loyalka P, Frazier OH, Jeevanandam V, Anderson AS, Kormos RL, Teuteberg JJ, Levy WC, Naftel DC, Bittman RM, Pagani FD, Hathaway DR, Boyce SW; HeartWare Ventricular Assist Device (HVAD) Bridge to Transplant ADVANCE Trial Investigators: Use of an intrapericardial, continuous-flow, centrifugal pump in patients awaiting heart transplantation. *Circulation* 125: 3191–3200, 2012
- Singh M, Shullo M, Kormos RL, Lockard K, Zomak R, Simon MA, Bermudez C, Bhama J, McNamara D, Toyoda Y, Teuteberg JJ: Impact of renal function before mechanical circulatory support on posttransplant renal outcomes. *Ann Thorac Surg* 91: 1348–1354, 2011
- Topkara VK, Dang NC, Barili F, Cheema FH, Martens TP, George I, Bardakci H, Oz MC, Naka Y: Predictors and outcomes of continuous veno-venous hemodialysis use after implantation of a left ventricular assist device. *J Heart Lung Transplant* 25: 404–408, 2006
- Alba AC, Rao V, Ivanov J, Ross HJ, Delgado DH: Predictors of acute renal dysfunction after ventricular assist device placement. *J Card Fail* 15: 874–881, 2009
- Copeland JG, Smith RG, Arabia FA, Nolan PE, Sethi GK, Tsau PH, McClellan D, Slepian MJ; CardioWest Total Artificial Heart Investigators: Cardiac replacement with a total artificial heart as a bridge to transplantation. *N Engl J Med* 351: 859–867, 2004
- Kaltenmaier B, Pommer W, Kaufmann F, Hennig E, Molzahn M, Hetzer R: Outcome of patients with ventricular assist devices and acute renal failure requiring renal replacement therapy. *ASAIO J* 46: 330–333, 2000
- Genovesi EA, Dew MA, Teuteberg JJ, Simon MA, Bhama JK, Bermudez CA, Lockard KL, Winowich S, Kormos RL: Early adverse events as predictors of 1-year mortality during mechanical circulatory support. *J Heart Lung Transplant* 29: 981–988, 2010
- Brisco MA, Kimmel SE, Coca SG, Putt ME, Jessup M, Tang WW, Parikh CR, Testani JM: Prevalence and prognostic importance of changes in renal function after mechanical circulatory support. *Circ Heart Fail* 7: 68–75, 2014
- Russell SD, Rogers JG, Milano CA, Dyke DB, Pagani FD, Aranda JM, Klodell Jr. CT, Boyle AJ, John R, Chen L, Massey HT, Farrar DJ, Conte JV; HeartMate II Clinical Investigators: Renal and hepatic function improve in advanced heart failure patients during continuous-flow support with the HeartMate II left ventricular assist device. *Circulation* 120: 2352–2357, 2009
- Sandner SE, Zimpfer D, Zrunek P, Dunkler D, Schima H, Rajek A, Grimm M, Wolner E, Wieselthaler GM: Renal function after implantation of continuous versus pulsatile flow left ventricular assist devices. *J Heart Lung Transplant* 27: 469–473, 2008
- Butler J, Geisberg C, Howser R, Portner PM, Rogers JG, Deng MC, Pierson 3rd RN: Relationship between renal function and left ventricular assist device use. *Ann Thorac Surg* 81: 1745–1751, 2006
- Rodrigues J, Alam A, Bernard C, Giannetti N, Podymow T: Secondary hemosiderosis on kidney biopsy in a patient with a left ventricular assist device. *Am J Med Sci* 347: 172–173, 2014
- Intermacs Users' Guide: Manual of Operations and Procedures Version 5.0, 2017. Available at: <https://www.uab.edu/medicine/intermacs/intermacs-documents>. Accessed June 30, 2017
- Kormos RL, Teuteberg JJ, Pagani FD, Russell SD, John R, Miller LW, Massey T, Milano CA, Moazami N, Sundareswaran KS, Farrar DJ; HeartMate II Clinical Investigators: Right ventricular failure in patients with the HeartMate II continuous-flow left ventricular assist device: Incidence, risk factors, and effect on outcomes. *J Thorac Cardiovasc Surg* 139: 1316–1324, 2010
- Puhlman M: Continuous-flow left ventricular assist device and the right ventricle. *AACN Adv Crit Care* 23: 86–90, 2012
- Strueber M, Larbalestier R, Jansz P, Zimpfer D, Fiane AE, Tsui S, Simon A, Schmitto JD, Khaghani A, Wieselthaler GM, Najarian K, Schueler S: Results of the post-market registry to evaluate the heartware left ventricular assist system (ReVOLVE). *J Heart Lung Transplant* 33: 486–491, 2014
- Segura AM, Gregoric I, Radovancevic R, Demirozu ZT, Buja LM, Frazier OH: Morphologic changes in the aortic wall media after support with a continuous-flow left ventricular assist device. *J Heart Lung Transplant* 32: 1096–1100, 2013
- Amir O, Radovancevic B, Delgado 3rd RM, Kar B, Radovancevic R, Henderson M, Cohn WE, Smart FW: Peripheral vascular reactivity in patients with pulsatile vs axial flow left ventricular assist device support. *J Heart Lung Transplant* 25: 391–394, 2006
- Kihara S, Litwak KN, Nichols L, Litwak P, Kameneva MV, Wu Z, Kormos RL, Griffith BP: Smooth muscle cell hypertrophy of renal cortex arteries with chronic continuous flow left ventricular assist. *Ann Thorac Surg* 75: 178–183, 2003
- Ootaki C, Yamashita M, Ootaki Y, Kamohara K, Weber S, Klatte RS, Smith WA, Massiello AL, Emancipator SN, Golding LA, Fukamachi K: Reduced pulsatility induces periarteritis in kidney: Role of the local renin-angiotensin system. *J Thorac Cardiovasc Surg* 136: 150–158, 2008

27. Rosner MH, Rastogi A, Ronco C: The cardiorenal syndrome. *Int J Nephrol* 2011: 982092, 2011
28. McCullough PA, Kellum JA, Haase M, Müller C, Damman K, Murray PT, Cruz D, House AA, Schmidt-Ott KM, Vescovo G, Bagshaw SM, Hoste EA, Briguori C, Braam B, Chawla LS, Costanzo MR, Tumlin JA, Herzog CA, Mehta RL, Rabb H, Shaw AD, Singbartl K, Ronco C: Pathophysiology of the cardiorenal syndromes: Executive summary from the eleventh consensus conference of the Acute Dialysis Quality Initiative (ADQI). *Contrib Nephrol* 182: 82–98, 2013
29. Mullens W, Abrahams Z, Francis GS, Sokos G, Taylor DO, Starling RC, Young JB, Tang WH: Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. *J Am Coll Cardiol* 53: 589–596, 2009
30. F Gnanaraj J, von Haehling S, Anker SD, Raj DS, Radhakrishnan J: The relevance of congestion in the cardio-renal syndrome. *Kidney Int* 83: 384–391, 2013
31. Cruz DN, Schmidt-Ott KM, Vescovo G, House AA, Kellum JA, Ronco C, McCullough PA: Pathophysiology of cardiorenal syndrome type 2 in stable chronic heart failure: Workgroup statements from the eleventh consensus conference of the Acute Dialysis Quality Initiative (ADQI). *Contrib Nephrol* 182: 117–136, 2013
32. James KB, McCarthy PM, Thomas JD, Vargo R, Hobbs RE, Sapp S, Bravo E: Effect of the implantable left ventricular assist device on neuroendocrine activation in heart failure. *Circulation* 92[Suppl]: II191–II195, 1995
33. Saito S, Westaby S, Piggot D, Dudnikov S, Robson D, Catarino PA, Clelland C, Nojiri C: End-organ function during chronic non-pulsatile circulation. *Ann Thorac Surg* 74: 1080–1085, 2002
34. Iwashima Y, Yanase M, Horio T, Seguchi O, Murata Y, Fujita T, Toda K, Kawano Y, Nakatani T: Effect of pulsatile left ventricular assist system implantation on Doppler measurements of renal hemodynamics in patients with advanced heart failure. *Artif Organs* 36: 353–358, 2012
35. James KB, McCarthy PM, Jaalouk S, Bravo EL, Betkowski A, Thomas JD, Nakatani S, Fouad-Tarazi FM: Plasma volume and its regulatory factors in congestive heart failure after implantation of long-term left ventricular assist devices. *Circulation* 93: 1515–1519, 1996
36. Demirozu ZT, Etheridge WB, Radovancevic R, Frazier OH: Results of HeartMate II left ventricular assist device implantation on renal function in patients requiring post-implant renal replacement therapy. *J Heart Lung Transplant* 30: 182–187, 2011
37. Quader MA, Kumar D, Shah KB, Fatani YI, Katlaps G, Kasirajan V: Safety analysis of intermittent hemodialysis in patients with continuous flow left ventricular assist devices. *Hemodial Int* 18: 205–209, 2014
38. Patel AM, Eduardo Rame J, Rudnick MR: How does the nephrologist manage an LVAD patient on chronic maintenance dialysis? *Semin Dial* 27: 284–288, 2014
39. Calenda BW, Smietana J, Casagrande L: Long-term hemodialysis via arteriovenous fistula in patients with continuous-flow left ventricular assist devices. *Artif Organs* 40: 712, 2016
40. Sasson T, Wing RE, Foster TH, Kashyap R, Butani D, Waldman DL: Assisted maturation of native fistula in two patients with a continuous flow left ventricular assist device. *J Vasc Interv Radiol* 25: 781–783, 2014
41. Schaeffers JF, Ertmer C: Native arteriovenous fistula placement in three patients after implantation of a left ventricular assist device with non-pulsatile blood flow. *Hemodial Int* 21: E54–E57, 2017
42. Thomas BA, Logar CM, Anderson AE: Renal replacement therapy in congestive heart failure requiring left ventricular assist device augmentation. *Perit Dial Int* 32: 386–392, 2012
43. Guglielmi AA, Guglielmi KE, Bhat G, Siemeck R, Tatooles AJ: Peritoneal dialysis after left ventricular assist device placement. *ASAIO J* 60: 127–128, 2014
44. *HeartMate II LVAS Clinical Operation & Patient Management*, Pleasanton, CA, Thoratec Corporation, 2008, pp 80
45. *HeartMate II LVAS Operating Manual: Featuring GoGear System Components (103884.E)*, Pleasanton, CA, Thoratec Corporation, 2012
46. Bennett MK, Roberts CA, Dordunoo D, Shah A, Russell SD: Ideal methodology to assess systemic blood pressure in patients with continuous-flow left ventricular assist devices. *J Heart Lung Transplant* 29: 593–594, 2010
47. Frazier OH, Rose EA, Oz MC, Dembitsky W, McCarthy P, Radovancevic B, Poirier VL, Dasse KA; HeartMate LVAS Investigators. Left Ventricular Assist System: Multicenter clinical evaluation of the HeartMate vented electric left ventricular assist system in patients awaiting heart transplantation. *J Thorac Cardiovasc Surg* 122: 1186–1195, 2001
48. Haddad M, Hendry PJ, Masters RG, Mesana T, Haddad H, Davies RA, Mussivand TV, Struthers C, Keon WJ: Ventricular assist devices as a bridge to cardiac transplantation: The Ottawa experience. *Artif Organs* 28: 136–141, 2004
49. Deng MC, Edwards LB, Hertz MI, Rowe AW, Keck BM, Kormos R, Naftel DC, Kirklin JK, Taylor DO; International Society for Heart and Lung Transplantation: Mechanical circulatory support device database of the International Society for Heart and Lung Transplantation: Third annual report–2005. *J Heart Lung Transplant* 24: 1182–1187, 2005
50. Feller ED, Sorensen EN, Haddad M, Pierson 3rd RN, Johnson FL, Brown JM, Griffith BP: Clinical outcomes are similar in pulsatile and nonpulsatile left ventricular assist device recipients. *Ann Thorac Surg* 83: 1082–1088, 2007
51. John R, Naka Y, Smedira NG, Starling R, Jorde U, Eckman P, Farrar DJ, Pagani FD: Continuous flow left ventricular assist device outcomes in commercial use compared with the prior clinical trial. *Ann Thorac Surg* 92: 1406–1413, discussion 1413, 2011
52. Borgi J, Tsiouris A, Hodari A, Cogan CM, Paone G, Morgan JA: Significance of postoperative acute renal failure after continuous-flow left ventricular assist device implantation. *Ann Thorac Surg* 95: 163–169, 2013
53. Sandner SE, Zimpfer D, Zrunek P, Rajek A, Schima H, Dunkler D, Grimm M, Wolner E, Wieselthaler GM: Renal function and outcome after continuous flow left ventricular assist device implantation. *Ann Thorac Surg* 87: 1072–1078, 2009
54. Starling RC, Naka Y, Boyle AJ, Gonzalez-Stawinski G, John R, Jorde U, Russell SD, Conte JV, Aaronson KD, McGee Jr. EC, Cotts WG, DeNofrio D, Pham DT, Farrar DJ, Pagani FD: Results of the post-U.S. Food and Drug Administration-approval study with a continuous flow left ventricular assist device as a bridge to heart transplantation: A prospective study using the INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support). *J Am Coll Cardiol* 57: 1890–1898, 2011
55. Park SJ, Milano CA, Tatooles AJ, Rogers JG, Adamson RM, Steidley DE, Ewald GA, Sundareswaran KS, Farrar DJ, Slaughter MS; HeartMate II Clinical Investigators: Outcomes in advanced heart failure patients with left ventricular assist devices for destination therapy. *Circ Heart Fail* 5: 241–248, 2012
56. Naik A, Akhter SA, Fedson S, Jeevanandam V, Rich JD, Koyner JL: Acute kidney injury and mortality following ventricular assist device implantation. *Am J Nephrol* 39: 195–203, 2014